In the British Journal of Cancer this week, researchers in Italy present the results of the ROSORC trial that tested sorafenib with interleukin-2 therapy versus sorafenib alone in patients with metastatic renal cell carcinoma. In this phase II study, 128 patients were randomized to receive sorafenib alone or with subcutaneous IL-2. After a median follow-up of 27 months, median progression-free survival was only 33 weeks with the combination therapy, compared with 30 weeks for monotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.